Oleg E. Akilov
Expertise in
6
conditions

Dr. Oleg E. Akilov

Dermatology
Office
580 S Aiken Ave Ste 200, 
Pittsburgh, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
6
conditions
Office
580 S Aiken Ave Ste 200, 
Pittsburgh, PA 

Overview

Oleg Akilov is a Dermatologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Akilov is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 7 clinical trials. Dr. Akilov is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in PA

Hospital Affiliations

Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Office
580 S Aiken Ave Ste 200, Pittsburgh, PA 15232
Other Locations
Office
3601 5th Ave Ste 5A, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Duvelisib, Nivolumab
Study Phase: Phase 1
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)
Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Micro needle array-Doxorubicin
Study Phase: Phase 1
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

81 Total Publications

IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.
IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.
Journal: Journal for immunotherapy of cancer
Published: May 16, 2026
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

UPMC Shadyside Dermatology

580 South Aiken Avenue, Suites 200 & 201, 
Pittsburgh, PA 
 (0.1 miles away)
412-681-1072
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Anuradha Bishnoi, MD, specializes in dermatology. She practices at UPMC North Hills Dermatology and UPMC Shadyside Dermatology. Dr. Bishnoi received her medical degree from Maharshi Dayanand University and completed her residency at the Postgraduate Institute of Medical Education and Research. Dr. Bishnoi is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Hypomelanotic Disorder, Vitiligo, Lichen Planus, and Melasma. Dr. Bishnoi is currently accepting new patients.

Expertise in
65
conditions
Expertise in
65
conditions
Referral may be required

Margaret S Lally MD

1382 Old Freeport Road, First Floor-Rear, 
Pittsburgh, PA 
 (6.5 miles away)
412-967-1192
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Margaret Lally is a Dermatologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Lally is highly rated in 65 conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Warts, Seborrheic Keratosis, and Rosacea. Dr. Lally is board certified in American Board Of Dermatology. Dr. Lally is currently accepting new patients.

Expertise in
3
conditions
Expertise in
3
conditions
Referral may be required
Before you request

Office

256 Merion Dr, 
Pittsburgh, PA 
 (7.5 miles away)
412-343-3636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Orin Goldblum is a Dermatologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Goldblum is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Psoriasis, Plaque Psoriasis, and Atopic Dermatitis. Dr. Goldblum is currently accepting new patients.

Frequently Asked Questions about Dr. Oleg E. Akilov

How do I make an appointment with Dr. Oleg E. Akilov?

You can book an appointment with Dr. Oleg E. Akilov by calling their office at 412-681-1072. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Oleg E. Akilov a top-rated expert for Mycosis Fungoides?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Oleg E. Akilov is classified as an Elite expert for Mycosis Fungoides, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Oleg E. Akilov specialize in?

While Dr. Oleg E. Akilov is a Dermatology, they have specific expertise in Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), and T-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Oleg E. Akilov participate in research or clinical trials?

Yes. Dr. Oleg E. Akilov has published 81 articles and abstracts on conditions like Mycosis Fungoides. You can view a list of Dr. Oleg E. Akilov's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Oleg E. Akilov accept my insurance?

Dr. Oleg E. Akilov accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 412-681-1072 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Akilov's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile